Market Overview

ZIKI Winds Down ePrescription Business


Analyst Jonathan Ruykhaver of ThinkEquity LLC maintains his "buy" rating on Zix Corporation (NASDAQ: ZIXI)(FREE stock trend analysis).

ZIXI has announced its intention to close its ePrescription business. Earlier Zix’s board of advisors worked for six months to explore the strategic options for this business. The divestiture would help the company to concentrate more effectively on its growing core business.

The analyst expects ZIKI to generate improved cash flows and profitability over time due to the divestiture. The company is enjoying strong fundamentals in its email encryption business, ThinkEquity adds.

Posted-In: Jonathan Ruykhaver ThinkEquityAnalyst Color Analyst Ratings


Related Articles (ZIXI)

View Comments and Join the Discussion!

Latest Ratings

PTONBank of AmericaInitiates Coverage On29.0
ITRICanaccord GenuityMaintains87.0
GWPHNeedhamInitiates Coverage On200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Dish Network Initiated as Neutral - Analyst Blog

Recession Holds Innovation Back